A carregar...
Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?
Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital admission are potential risk factors for acquiring infection with its causative pathogen, severe acute respiratory syndrome coronavirus−2 (SARS-CoV-...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7344199/ https://ncbi.nlm.nih.gov/pubmed/32714874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01193 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|